Page 94 - NobleCon19revC2_Neat

Health Care
Date November 21, 2023 Health Care
52wk High $1.39
52wk Low $0.47 GeoVax Labs, Inc. GOVX $0.53
1900 Lake Park Drive
Smyrna, GA 30080

(USD - in millions) www.geovax.com
Market Cap 14.2
Enterprise 1.5
Basic Shares Out. 26.70 COMPANY OVERVIEW
Float 26.30
Institutional Holdings 5.77% Detailed Analysis:Channelchek.com
Short Interest 0.84
Avg. 90-Day Volume 0.25 GeoVax Labs, Inc. is a clinical-stage biotechnology company
developing novel therapies and vaccines for cancers and many of the
world’s most threatening infectious diseases. The company’s lead
program in oncology is a novel oncolytic solid tumor gene-directed
EPS Data therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial
for advanced head and neck cancers. GeoVax’s lead infectious
2021 2022 2023 disease candidate is GEO-CM04S1, a next-generation COVID-19
CQ1 (0.29) (0.34) (0.15) vaccine targeting high-risk immunocompromised patient populations.
CQ2 (0.21) (0.18) (0.22)

CQ3 (0.31) (0.17) (0.32)
CQ4 (2.24) (0.20) (0.26)
CY (3.04) (0.83) (0.97) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 0.34
ROE (ttm) -116.18
Debt-to-Total Cap. (mrq) N/A
Fiscal Year End 31-Dec
S
1900 Lake Pa myrna GA 30080

Key Executives
CEO: Dodd, David
CFO: Reynolds, Mark
COO: N/A
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
Following the conference, complete video library of presentations will be
rleboyer@noblelsp.com available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures